

# Kotak Healthcare Fund

An open ended equity scheme investing in Pharma, Healthcare & allied sectors

30<sup>th</sup> April 2025



## Fund Facts

**Allotment Date:** 11 December 2023.

**Benchmark:** Nifty Healthcare Index TRI

**AUM:** ₹413.97 crs



## Fund Manager\*

Ms. Shibani Sircar Kurian, Mr. Dhananjay Tikariha & Mr. Abhishek Bisen



## Minimum Investment Amount

**Initial & Additional Investment**  
₹100 and any amount thereafter

**Systematic Investment Plan (SIP)**  
₹100 and any amount thereafter

**Ideal Investments Horizon**  
5 years & above



## Risk Ratios

§Standard Deviation	18.61%
§Beta	0.97
§Sharpe <sup>##</sup>	0.73
Portfolio Turnover	39.59%
<sup>^^</sup> P/E	49.24
<sup>^^</sup> P/BV	5.88



## Total Expense Ratio\*\*

Regular Plan: 2.40%  
Direct Plan: 0.80%



## About the Fund

- The fund invests in securities of companies engaged in Pharma, Healthcare, and allied sectors.
- The Fund uses a bottom-up approach to select stocks, evaluating companies based on their business, management, and valuation to identify those offering growth at a reasonable price.
- The fund has flexibility to invest across all market capitalisation.



## Portfolio Action

- Indian Pharma Market continues to grow at high single digits and better run companies have been able to grow faster than IPM consistently with steady profitability.
- Companies which have been able to build strong brands in chronic therapies are growing faster than the market with improving profitability.
- US generics pricing pressure has largely stabilised and the fund has exposure to companies benefitting from the same. However, The uncertainty on the imposition of tariffs by the US is also weighing on the sector.
- We are positive on Domestic Branded generics and CDMO. Domestic Branded business has structural growth because of improving affordability and access to healthcare.
- We positive on Hospitals and diagnostics, growth in these segments is structural but we remain mindful of valuations for some of the names.
- Hospitals segment continues to grow on the back of moderate ARPOB (Average Revenue per operating bed) improvement and bed addition. Medium term outlook is strong because of strong bed addition pipeline. Major portion of bed addition is brownfield for leading hospitals allowing faster breakeven and higher RoCEs



## Market Cap<sup>^^</sup>

Month	Large (%)	Mid (%)	Small (%)	Debt & Money Market (%)
April-25	38.1	30.5	29.8	1.6
March-25	38.8	30.2	29.3	1.7
February-25	39.5	29.6	29.6	1.3
January-25	37.1	27.0	34.1	1.8
December-24	39.2	24.2	35.2	1.4
November-24	41.1	25.1	33.0	0.8



## Top 10 Stocks<sup>^^</sup>

Stocks	% to Net Assets	Stocks	% to Net Assets
Sun Pharmaceuticals Industries Ltd.	17.70%	Lupin Ltd.	3.64%
Max Healthcare Institute Ltd.	8.09%	Aurobindo Pharma Ltd.	3.59%
Cipla Ltd.	6.44%	Torrent Pharmaceuticals Ltd.	3.37%
Divi S Laboratories Ltd.	5.29%	Apollo Hospitals Enterprises Ltd.	3.37%
JB Chemicals & Pharmaceuticals Ltd.	3.70%	Jubilant Pharmova Limited	3.04%

## Top Sector^^

Sector	30th April 2025			31st March 2025			28th February 2025		
	Scheme	Benchmark	Ow/Uw	Scheme	Benchmark	Ow/Uw	Scheme	Benchmark	Ow/Uw
Healthcare	98.12	100.00	-1.88	98.11	100.00	-1.89	98.50	100.00	-1.50
Not Classified	1.88	-	1.88	1.89	-	1.89	1.50	-	1.50

^^Source: <https://www.kotakmf.com/mutual-funds/equity-funds/kotak-healthcare-fund/reg-g>

The stocks/sectors mentioned do not constitute any kind of recommendation and are for information purpose only.

Kotak Mahindra Mutual Fund may or may not hold position in the mentioned stock(s)/sector(s).

OW – Overweight, UW – Underweight

## What In and What's Out: April 2025<sup>s</sup>

New Entry	Complete Exit
AMI Organics Ltd	AMI Organics Ltd

## Scheme Performance - Regular Plan Growth Option

As on 30th April 2025	Kotak Healthcare Fund - Reg - Growth	Nifty Healthcare Index TRI #	ALPHA	Nifty 50 TRI ##	Kotak Healthcare Fund - Reg - Growth (₹)	Nifty Healthcare Index TRI # (₹)	Nifty 50 TRI ## (₹)
Since Inception	20.75%	26.52%	-5.77%	12.38%	12,988	13,856	11,757
Last 1 Year	14.85%	18.03%	-3.19%	9.01%	11,485	11,803	10,901

Scheme Inception date is 11/12/2023. Mr. Abhishek Bisen, Ms. Shibani Sircar Kurian & Mr. Dhananjay Tikariha have been managing the fund since 11/12/2023. Different plans have different expense structure. **The performance details provided herein are of Regular Plan - Growth Option.** Past performance may or may not be sustained in future. All payouts during the period have been reinvested in the units of the scheme at the then prevailing NAV. Returns >= 1 year: CAGR (Compounded Annualised Growth Rate). Note: Point to Point (PTP) Returns in INR shows the value of 10,000/- investment made at inception. Source: ICRA MFI Explorer. # Name of Scheme Benchmark. ## Name of Additional Benchmark. TRI - Total Return Index, In terms of para 6.14 of SEBI Master circular No. SEBI/HO/IMD/IMD-PoD-1/P/CIR/2024/90 dated June 27, 2024, the performance of the scheme is benchmarked to the Total Return variant (TRI) of the Benchmark Index instead of Price Return Variant (PRI). Alpha is difference of scheme return with benchmark return.

## Scheme Performance - Direct Plan Growth Option

As on 30th April 2025	Kotak Healthcare Fund - Dir - Growth	Nifty Healthcare Index TRI #	ALPHA	Nifty 50 TRI ##	Kotak Healthcare Fund - Dir - Growth (₹)	Nifty Healthcare Index TRI # (₹)	Nifty 50 TRI ## (₹)
Since Inception	22.77%	26.52%	-3.75%	12.38%	13,289	13,856	11,757
Last 1 Year	16.74%	18.03%	-1.29%	9.01%	11,674	11,803	10,901

Scheme Inception date is 11/12/2023. Mr. Abhishek Bisen, Ms. Shibani Kurian & Mr. Dhananjay Tikariha have been managing the fund since 11/12/2023. Different plans have different expense structure. **The performance details provided herein are of Direct Plan - Growth Option.** Past performance may or may not be sustained in future. All payouts during the period have been reinvested in the units of the scheme at the then prevailing NAV. Returns >= 1 year: CAGR (Compounded Annualised Growth Rate). Note: Point to Point (PTP) Returns in INR shows the value of 10,000/- investment made at inception. Source: ICRA MFI Explorer. # Name of Scheme Benchmark. ## Name of Additional Benchmark. TRI - Total Return Index, In terms of para 6.14 of SEBI Master circular No. SEBI/HO/IMD/IMD-PoD-1/P/CIR/2024/90 dated June 27, 2024, the performance of the scheme is benchmarked to the Total Return variant (TRI) of the Benchmark Index instead of Price Return Variant (PRI). Alpha is difference of scheme return with benchmark return.

## SIP Performance - Regular Plan Growth Option

Monthly SIP of Rs 10,000	Since Inception	1 year
Total amount invested (₹)	1,70,000	1,20,000
Total Value as on 30th April 2025 (₹)	1,83,308	1,22,626
<b>Scheme Returns (%)</b>	<b>10.57</b>	<b>4.13</b>
Nifty Healthcare Index (TRI) Returns (%)	14.57	8.10
Alpha*	-4.00	-3.98
Nifty Healthcare Index (TRI) (₹)#	1,88,331	1,25,129
Nifty 50 (TRI) (₹)^	1,79,444	1,22,955
Nifty 50 (TRI) Returns (%)	7.50	4.65

Scheme Inception : - December 11, 2023. The returns are calculated by XIRR approach assuming investment of Rs.10,000/- on the 1st working day of every month. Since Inception returns are assumed to be starting from the inception date of the Scheme and calculated accordingly. XIRR helps in calculating return on investments given an initial and final value and a series of cash inflows and outflows and taking the time of investment into consideration. **The SIP Performance is for Regular Plan – Growth Option.** Different plans have different expense structure.

# Benchmark; ^ Additional Benchmark. TRI – Total Return Index, In terms of para 6.14 of SEBI Master circular No. SEBI/HO/IMD/IMD-PoD-1/P/CIR/2024/90 dated June 27, 2024, the performance of the scheme is benchmarked to the Total Return variant (TRI) of the Benchmark Index instead of Price Return Variant (PRI). Alpha is difference of scheme return with benchmark return. \*All payouts during the period have been reinvested in the units of the scheme at the then prevailing NAV.

### Disclosures:

§Source: ICRAMFI Explorer. Standard Deviation is calculated on Annualized basis using 3 years history of monthly returns.

\*\*Total Expense Ratio includes applicable B30 fee and GST as on 30th April 2025.



##Risk Rate assumed to be 6.00% (FBIL Overnight MIBOR rate as on 30th April 2025)

\*To Know More about Fund Managers Top 3 & Bottom 3 scheme performance,

[https://www.kotakmf.com/documents/Funds\\_Managed\\_by\\_Fund\\_Managers\\_Reg\\_Plan%20V3](https://www.kotakmf.com/documents/Funds_Managed_by_Fund_Managers_Reg_Plan%20V3)

[https://www.kotakmf.com/documents/Funds\\_Managed\\_by\\_Fund\\_Managers\\_Direct\\_Plan%20V3](https://www.kotakmf.com/documents/Funds_Managed_by_Fund_Managers_Direct_Plan%20V3)

## Riskometer

 <p><b>Scheme Risk-o-meter</b></p> <p>The risk of the scheme is Very High</p>	 <p><b>Benchmark Nifty 200 Total Return Index Risk-o-meter</b></p> <p>The risk of the benchmark is Very High</p>	<h3>KOTAK HEALTHCARE FUND</h3> <p>An open ended equity scheme investing in Pharma, Healthcare &amp; allied sectors</p> <p><b>This product is suitable for investors who are seeking:*</b></p> <ul style="list-style-type: none"> <li>• Long-term capital growth.</li> <li>• Investment in portfolio of predominantly equity &amp; equity related securities of companies engaged in Pharma, Healthcare &amp; allied sectors.</li> </ul> <p>*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.</p>
--	---	---

For latest Riskometer, investors may refer to an addendum issued or updated on website at [www.kotakmf.com](https://www.kotakmf.com)

## Disclaimer

The information contained in this (document) is extracted from different public sources. All reasonable care has been taken to ensure that the information contained herein is not misleading or untrue at the time of publication. This is for the information of the person to whom it is provided without any liability whatsoever on the part of Kotak Mahindra Asset Management Co Ltd or any associated companies or any employee thereof. We are not soliciting any action based on this material and is for general information only. Investors should consult their financial advisors if in doubt about whether the product is suitable for them before investing.

The document includes statements/opinions which contain words or phrases such as "will", "believe", "expect" and similar expressions or variations of such expressions, that are forward looking statements. Actual results may differ materially from those suggested by the forward looking statements due to risk or uncertainties associated with the statements mentioned with respect to but not limited to exposure to market risks, general and exposure to market risks, general economic and political conditions in India and other countries globally, which have an impact on the services and/or investments, the monetary and interest policies of India, inflation, deflation, unanticipated turbulence in interest rates, foreign exchange rates, equity prices or other rates or prices etc.

This is not intended for distribution or use by any person in any jurisdiction where such distribution would be contrary to local law or regulation. The distribution of it, in certain jurisdictions may be restricted or totally prohibited and accordingly, persons who come into possession of this material are required to inform themselves about, and to observe, any such restrictions.

Past performance may or may not be sustained in future. For detailed portfolio and related disclosures for the scheme please refer our website <https://www.kotakmf.com/Information/forms-and-downloads>. The portfolio and its composition is subject to change and the same position may or may not be sustained in future. The fund manager may make the changes, as per different market conditions and in the best interest of the investors. To view the latest complete performance details of the Scheme kindly refer to the factsheet on our website <https://www.kotakmf.com/Information/forms-and-downloads>.

Investors may consult their financial expert before making any investment decision.

**MUTUAL FUND INVESTMENTS ARE SUBJECT TO MARKET RISKS, READ ALL SCHEME RELATED DOCUMENTS CAREFULLY.**